bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 3.47M -48.5% |
| Revenue (ttm) | 5.66M -35.8% |
| Net Income | -15.88M |
| EPS | -5.86 |
| Shares Out | 4.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 260,117 |
| Open | 0.7860 |
| Previous Close | 0.7782 |
| Day's Range | 0.7420 - 0.7860 |
| 52-Week Range | 0.6930 - 13.5000 |
| Beta | -1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2
bioAffinity Technologies (BIAF) announced continued acceleration in commercial sales for CyPath Lung, its noninvasive lung cancer diagnostic, with more than 200% growth year-over-year. The number of t...
bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
BioAffinity will present preclinical findings on small interfering RNAs
bioAffinity Technologies (BIAF) will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs that kill squamous and basal skin cancer cells in vitro while leavin...
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...
bioAffinity Technologies Announces Closing of $3.2 Million Offering
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...
BioAffinity Technologies prices 4M shares at 80c in public offering
bioAffinity Technologies (BIAF) priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2M, before deducting agent fees and other estimated expenses...
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces pricing of a public offering.
BioAffinity announces webinar for program to advance veteran lung health
bioAffinity Technologies (BIAF) announced a webinar on July 21, 2026, featuring clinical experts discussing emerging approaches to lung health screening and early detection for veterans at increased r...
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces joint webinar with Philips and 4DMedical on diagnostic and imaging technologies to support lung health in veterans.
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on June 16, 2026, providing details about a securities offering with the SEC.
BioAffinity Technologies files to sell 2.63M shares of common stock
WallachBeth Capital is acting as the underwriter for this offering.
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on June 12, 2026, providing details about a securities offering with the SEC.
BioAffinity Technologies announces SAB to host webinar on CyPath Lung
bioAffinity Technologies (BIAF) announced the Society for Advanced Bronchoscopy, SAB, will host a webinar on CyPath Lung’s expanding role in pulmonary, oncology and surgical practices for the detectio...
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--The Society for Advanced Bronchoscopy to host June 16 webinar featuring CyPath Lung's role in detection and management of early-stage lung cancer.
BioAffinity Technologies announces notification of Mexico patent allowance
bioAffinity Technologies (BIAF) announced it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting the like...
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for Mexican patent on methods of predicting the likelihood of lung cancer using flow cytometry.
BioAffinity says CyPath Lung test unit sales achieved monthly record in April
BioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to…
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today a...
BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year
Reports revenue $1.4M vs. $1.9M last year. “Our first quarter results demonstrate continued momentum for CyPath Lung in the marketplace. As more and more physicians adopt CyPath Lung and share…
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection ...
bioAffinity Technologies Earnings release: Q1 2026
bioAffinity Technologies released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
bioAffinity Technologies Quarterly report: Q1 2026
bioAffinity Technologies has published its Q1 2026 quarterly earnings report on May 8, 2026.
BioAffinity Technologies files to sell 497,483 shares of common stock for holder
17:09 EDT BioAffinity Technologies (BIAF) files to sell 497,483 shares of common stock for holder